The role of sex-specific results reporting in cardiovascular disease

Cardiology in Review

Volumn 15, Issue 6, 2007, Pages 275-278

  Blauwet, Lori A ^a   Redberg, Rita F ^b  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Gender; Heart disease; Outcomes; Women

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIAGNOSTIC TEST; DRUG BLOOD LEVEL; DRUG FATALITY; ELECTROCARDIOGRAM; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEART INFARCTION; HEART PROARRHYTHMIA; HUMAN; MEDICAL RESEARCH; NON INVASIVE PROCEDURE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; HUMANS; RESEARCH DESIGN; SEX FACTORS; WOMEN'S HEALTH;

EID: 37349106280     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318158b45b     Document Type: Review

References (40)

1. Women. World Heart Federation. Available at www.worldheart.org/awareness- women.php.
2. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
3. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499-510.
4. United States Public Service. Report of the Public Service Task Force on Women's Health Issues. Public Health Rep. 1985;100:73.
5. NIH Guide for Grants and Contracts; 1986.
6. General Accounting Office, National Institutes of Health. Problems in implementing policy on women in study populations. GAO/HRD-90-38; 1990.
7. NIH Guide for Grants and Contracts; 1990.
8. Federal Register. NIH guidelines on the inclusion of women and minorities as subjects in clinical research. 1994;59:14508-14513.
9. General Accounting Office, National Institutes of Health. NIH has increased its efforts to include women in research. GAO/HEHS-00-96; 2000.
10. Mosca L, Mochari H, Christian A, et al. National study of women's awareness, preventive action, and barriers to cardiovascular health. Circulation. 2006;113:525-534.
11. Sibley C, Blumenthal RS, Bairy Merz CN, et al. Limitations of current cardiovascular disease risk assessment strategies in women. J Womens Health (Larchmt). 2006;14:54-56.
12. Michos ED, Nasir K, Braunstein JB, et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis. 2006;184:201-206.
13. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol. 2007;49:1230-1250.
14. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.
15. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798.
16. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
17. McSweeney JC, Cody M, O'Sullivan P, et al. Women's early warning symptoms of acute myocardial infarction. Circulation. 2003;108:2619-2623.
18. Kim C, Schaaf CH, Maynard C, et al. Unstable angina in the myocardial infarction triage and intervention registry (MITI): short- and long-term outcomes in men and women. Am Heart J. 2001;141:73-77.
19. Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation. 2005;111:682-696.
20. Mieres JH, Shaw LJ, Hendel RC, et al. American Society of Nuclear Cardiology consensus statement: task force on women and coronary artery disease-the role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women. J Nucl Cardiol. 2003;10:95-101.
21. Lansky AJ, Costa RA, Mooney M, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol. 2005;45:1180-1185.
22. Lansky AJ, Pietras C, Costa RA, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2005;111:1611-1618.
23. Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation. 2006;114:1344-1346.
24. Jochmann N, Stangl K, Garbe E, et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular disease. Eur Heart J. 2005;26:1585-1595.
25. Luzier AB, Killian A, Wilton JH, et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 1999;66:594-601.
26. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol. 1999;47:111-114.
27. Strocchi E, Malini PL, Valtancoli G, et al. Cough during treatment with angiotensin-converting enzyme inhibitors: analysis of predisposing factors. Drug Invest. 1992;4:69-72.
28. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D-44D.
29. Pratt CM, Camm AJ, Cooper W, et al. Mortality in the survival with ORal D-Sotalol (SWORD) trial: why did patients die? Am J Cardiol. 1998;81:869-876.
30. Lehmann MH, Hardy S, Archibald D, et al. Sex differences in risk of torsades de pointes with d,l-sotalol. Circulation. 1996;94:2535-2541.
31. Makker RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
32. Rathore SS, Curtis JP, Wang Y, et al. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-1411.
33. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med. 1999;341:217-225.
34. King KM, Ghali WA, Faris PD, et al. Sex differences in outcomes after cardiac catheterization: effect modification by treatment strategy and time. JAMA. 2004;291:1220-1225.
35. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol. 1979;44:53-59.
36. Mallik S, Vaccarino V. Outcomes of thrombolytic therapy for acute myocardial infarction in women. Prog Cardiovasc Dis. 2004;47:58-71.
37. Vaccarino V, Abramson JL, Veledar E, et al. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation. 2002;105:1176-1181.
38. Department of Health and Human Services, National Institutes of Health. Monitoring adherence to the NIH policy on the inclusion of women and minorities as subjects in clinical research. Bethesda, MD: National Institutes of Health; 2007.
39. Grady D, Chaput L, Kristof M. Diagnosis and Treatment of Coronary Heart Disease in Women: Systemic Reviews of Evidence on Selected Topics. Evidence Report/Technology Assessment No. 81. AHRQ publication No. 03-E037. Rockville, MD: Agency for Healthcare Research and Quality; 2003.
40. Blauwet LA, Hayes SN, McManus D, et al. Low rate of sex-specific result reporting in cardiovascular trials. Mayo Clin Proc. 2007;82:166-170.